Aurobindo Pharma has successfully moved one step closer to completing its strategic acquisition of U.S.-based generic drug manufacturer Lannett Company after the U.S. Federal Trade Commission (FTC) approved the transaction subject to certain divestiture conditions.
The FTC announced that Aurobindo will divest four generic pharmaceutical products to Quagen Pharmaceuticals as part of a consent agreement designed to preserve competition in the U.S. generic medicines market. With this requirement in place, the proposed acquisition of Lannett can move forward toward completion.
From Aurobindo's perspective, the FTC decision represents a significant regulatory milestone rather than a setback. The company had announced its plan to acquire Lannett for approximately 250 million USD as part of its long-term strategy to strengthen its manufacturing footprint and product portfolio in the United States. The acquisition is expected to expand Aurobindo's presence in complex generics, controlled substances, and specialty pharmaceutical segments.
Under the agreement, Aurobindo will divest four generic products that the FTC identified as having potential competitive overlap with Lannett's portfolio. These include medicines used for organ transplant patients, cholesterol management, radiation therapy-related dry mouth, and stomach acid reduction. The FTC concluded that transferring these products to another manufacturer would maintain market competition while allowing the broader transaction to proceed.
Industry observers view the FTC's approval as a positive development for Aurobindo because it removes a major regulatory uncertainty surrounding the acquisition. The company had previously expressed confidence that the transaction would withstand antitrust scrutiny and deliver strategic benefits in the world's largest pharmaceutical market.
The acquisition will provide Aurobindo with ownership of Lannett's manufacturing facility in Seymour, Indiana, which has substantial production capacity and supports the company's goal of increasing its U.S.-based manufacturing operations. The deal is also expected to strengthen Aurobindo's position in several specialized generic drug categories and provide opportunities for future growth through Lannett's product pipeline.
With the FTC issue now substantially resolved through the divestiture agreement, Aurobindo is expected to focus on completing the remaining closing formalities and integrating Lannett's operations into its global pharmaceutical business. The development reinforces Aurobindo's commitment to expanding its presence in the United States while complying with regulatory requirements aimed at protecting competition and patient access to affordable medicines.
